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Background and purpose: Hypomimia is a prominent clinical feature in people
with Parkinson’s disease (PD), but it remains under-investigated. We aimed to
examine the clinical correlates of hypomimia in PD and to determine whether
this is a levodopa-responsive sign.
Methods: We included 89 people with PD. Hypomimia was assessed from
digital video recordings by movement disorder specialists. Clinical evaluation
included use of the Unified Parkinson’s Disease Rating Scale part III
(UPDRS-III), and assessment of motor and non-motor symptoms using stan-
dardized clinical scales. The relationships between hypomimia and other clini-
cal data were analysed using Mann–Whitney U-tests and regression analysis.
Results: Hypomimia occurred in up to 70% of patients with PD. Patients
with hypomimia had worse UPDRS-III ’off-medication’ scores, mainly driven
by bradykinesia and rigidity subscores. Patients with hypomimia also had
worse apathy than patients without hypomimia. Finally, we found that hypo-
mimia was levodopa-responsive and its improvement mirrored the change by
levodopa in axial motor symptoms.
Conclusion: Our study provides novel information regarding the clinical cor-
relates of hypomimia in people with PD. A better understanding of hypomi-
mia may be relevant for improving treatment and quality of life in PD.
Introduction
People with Parkinson’s disease (PD) often manifest
severe loss of facial expression, referred to as hypomi-
mia [1,2]. However, despite being one of the hallmark
features of PD, hypomimia has been characterized in
a relatively limited number of clinical and neurophysi-
ological studies [3,4].
Well-defined data on the prevalence of hypomimia
in PD are also lacking. Together with other orofacial
symptoms (speech and swallowing impairment, sialor-
rhoea), hypomimia has been associated with more sev-
ere motor symptoms [4]. However, it is not known
whether hypomimia is influenced by the demographic
features of patients, that is, age, gender and disease
duration. It is also unclear whether hypomimia paral-
lels the severity of appendicular cardinal motor signs
(bradykinesia and rigidity) or, rather, is associated
with axial signs (posture, gait and balance disorders)
or non-motor features such as cognitive and psychi-
atric symptoms. Moreover, data on the impact of
hypomimia on quality of life and social well-being of
PD patients are limited [5,6]. Finally, although hypo-
mimia seems to be a better predictor of basal ganglia
dopaminergic denervation compared with other
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parkinsonian signs [7], no clear information is avail-
able on the effects of levodopa on this clinical feature.
Given this background, we aimed to address the
following research questions: (i) is the severity of
hypomimia in PD influenced by demographic fea-
tures?; (ii) does hypomimia parallel the impairment of
appendicular, axial or motor signs?; (iii) is hypomimia
associated with non-motor symptoms of PD, including
cognitive and psychiatric symptoms? and (iv) is hypo-
mimia levodopa-responsive?
Accordingly, we tested possible correlations between
patients’ hypomimia and their demographic and clini-
cal features. We evaluated other clinical correlates of
hypomimia by analysing its relationship with appendic-
ular or axial motor signs (orofacial, speech and gait).
We also extensively assessed non-motor symptoms,
such as cognitive and neuropsychiatric deficits and we
tested whether they were related to the severity of
hypomimia. Finally, we assessed the effect of levodopa
on hypomimia and compared it to changes in other
parkinsonian signs after a levodopa challenge test.
Methods
Patients
Consecutive patients with PD attending the Move-
ment Disorders Clinic at St George’s University
Hospital (London, UK) were invited to participate in
the study. The diagnosis of idiopathic PD was con-
firmed according to Movement Disorder Society
(MDS) clinical diagnostic criteria [8]. We excluded
patients with dementia as per clinical assessment. We
also excluded patients with a history of Bell’s palsy,
maxillofacial deficits, or injection of botulinum toxin
in facial muscles for cosmetic or therapeutic purposes
which could interfere with facial movements.
Demographic and clinical data were gathered
including gender, age, age at disease onset and disease
duration. Information about PD medications was col-
lected and the total levodopa equivalent daily dose
(LEDD) and LEDD dopamine agonists were calcu-
lated for each patient [9]. All patients provided written
informed consent to participate according to the Dec-
laration of Helsinki, and the research ethics board
approved the study (IRAS number 259146).
Outcome measures
Patients with PD were assessed after a 12-h overnight
medication withdrawal in the practically defined ’off-
medication’ (OFF) condition [10]. The last dose of
prolonged-release dopamine agonist medication was
taken the morning before the test. The patients were
also assessed in their best ’on-medication’ (ON) condi-
tion 60–90 min after taking a dose of levodopa corre-
sponding to their usual morning LEDD plus 50%
(supramaximal dose = 150%).
In both OFF and ON conditions, motor symptom
severity and disease stage were evaluated using the
Unified Parkinson’s Disease Rating Scale part III
(UPDRS-III) and the Hoehn and Yahr stage. Presence
of hypomimia was defined according to a score ≥ 2 on
the UPDRS-III, item 19 (‘slight but definitely abnormal
diminution of facial expression’). Bradykinesia score
was calculated as the sum of the sub-items finger taps
(left and right), hand movement (left and right), rapid
alternate movements of hands (right and left), leg agility
(right and left), and body bradykinesia of the UPDRS-
III (items 23–26). Axial motor features were expressed
in terms of ’axial score’, which was calculated as the
sum of the following items of the UPDRS-III: 18
(speech), 22 (rigidity of neck), 27 (arising from chair),
28 (posture), 29 (gait) and 30 (postural stability) [11]. In
addition, we computed the variable ‘appendicular score’
as the sum of UPDRS-III tremor , bradykinesia and
rigidity scores of right and left limbs. Magnitude of
change after levodopa was calculated for UPDRS-III
item 19, axial and appendicular scores as follows: delta =
(score OFF-score ON)/score OFF.
Dyskinesia was rated with the Rush Dyskinesia rat-
ing scale. The Non-Motor Symptoms Scale was used
to evaluate severity of non-motor symptoms [12].
Orofacial symptoms were measured using the Rad-
boud Oral Motor Inventory for PD (ROMP), a self-ad-
ministered questionnaire that encompasses three
subscales evaluating difficulties with speech, swallowing
disturbances, and drooling of saliva [13]. Gait
impairment and falls were investigated with the self-
administered Gait and Falls Questionnaire (GFQ) [14].
Mood and psychiatric symptoms were explored
using the Hamilton Anxiety [15] and Depression Rat-
ing Scale [16] and Apathy Evaluation Scale [17]. Qual-
ity of life was measured using the 39-item Parkinson’s
Disease Questionnaire (PDQ-39) [18].
All PD patients underwent an extensive neuropsycho-
logical test battery, including tests to assess attention,
executive functions, language, memory, and visuospatial
functions. A minimum of two tests were administered for
each domain (Table S1). Patients were categorized as
having normal cognition or mild cognitive impairment
(MCI) according to the Level II International Parkinson
andMovementDisorders Society criteria [19].
Statistical analysis
After checking for normal distribution of the variables
by Kolmogorov–Smirnov test, group comparisons
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were performed using either a t-test or Mann–Whitney
U-test for continuous variables and a chi-squared or
Fisher’s exact test for categorical data. Bonferroni
correction was used to account for multiple compar-
isons. To test the effect of levodopa on hypomimia,
we performed a repeated-measure ANOVA with ‘group’
as between-group factor (two levels: PD with hypomi-
mia, PD without hypomimia) and ‘medication’ as a
within-group factor (two levels: OFF, ON). Condi-
tional on significant F values, we used post hoc pair-
wise comparisons within each group.
Univariable linear regression analyses were per-
formed to explore the relationship between facial
expression at baseline (as per UPDRS-III item 19)
and the following variables: age, gender, disease dura-
tion, LEDD, axial and appendicular scores of
UPDRS-III.. To explore the association between the
response to levodopa of facial expression and demo-
graphical and clinical variables, we employed univari-
able linear regression analysis with delta value of
UPDRS-III item 19 as dependent variable. The vari-
ables that were significantly associated with outcomes
at the univariable level were included in the multivari-
able models.
For all statistical procedures we used SPSS Statis-
tics version 25 and the significance level was set as
P < 0.05 in all tests.
Results
We included 89 patients with PD whose clinical and
demographic data are shown in Table S2. Fifty-seven
(64%) patients with PD were classified as having PD
with hypomimia (PD-HYP group) and 32 patients
(36%) as having PD without hypomimia (PD-no-
HYP group). There was no difference in age, sex, dis-
ease duration, total LEDD or LEDD dopamine ago-
nists between the groups (Table 1).
Clinical correlates of hypomimia in PD
We found a significant between-group difference in
terms of severity of motor symptoms in the OFF
condition. Specifically, the PD-HYP group had sig-
nificantly worse UPDRS-III total score, body
bradykinesia, rigidity and axial subscores compared
to the PD-no-HYP group (Table 1). Conversely,
there were no between-group differences when evalu-
ating tremor subscores and gait and balance symp-
toms as per the GFQ. Non-motor symptoms
(P = 0.04) and apathy (P < 0.0001) were more sev-
ere in the PD-HYP group compared to the PD-no-
HYP group (Table 1), however, non-motor symp-
toms did not survive after adjusting for multiple
comparisons.
Table 1 Comparison of demographic and clinical characteristics of Parkinson’s disease patients with and without hypomimia
No hypomimia (N = 32) Hypomimia (N = 57) P
Age, years 60.3  6.75 61.8  6.5 0.2
Women, n 15 18 0.1
Disease duration, years 9.5  3.6 11.2  4.9 0.1
Age at onset, years 51.1  7.7 50.6  7.6 0.9
Total LEDD 938  470.9 1028.4  371.6 0.3
Dopamine agonists LEDD 206.5  150.1 189.3  167.3 0.5
UPDRS-I score 1.8  2.1 2.3  2.1 0.1
UPDRS-II score 14.1  6.1 18.5  7.2 0.01
UPDRS-III - OFF score 34.6  15.0 51.4  13.9 <0.0001
Bradykinesia OFF subscore 13.6  6.3 19.8  6.5 <0.0001
Rigidity OFF subscore 7.4  3.8 12.1  4.8 <0.0001
Tremor OFF subscore 6.1  5.2 5.7  5.5 0.5
Axial OFF subscore 7.2  4.5 10.4  4.5 0.001
UPDRS-IV score 5.83  3.392 6.2  3.6 0.9
RDRS score 3.63  3.586 3.9  3.9 0.8
% improvement at levodopa challenge test 59.1  15.9 52.9  19.7 0.2
GFQ score 16.9  12.9 20.1  14.6 0.4
NMSS total score 58.3  31.5 76.9  43.4 0.04
HDRS score 6.7  4.3 8.1  7.0 0.7
HARS score 9.4  6.8 10.6  10.2 0.9
Apathy evaluation scale score 5.8  6.5 11.2  7.1 <0.0001
Values are mean  SD, unless otherwise indicated. P value corrected for multiple comparisons 0.002. ADL, activities of daily living; GFQ,
Gait and Fall Questionnaire; HARS, Hamilton Anxiety Rating Scale; HDRS, Hamilton Depression Rating Scale; LEDD, levodopa equivalent
daily dose; MOCA, Montreal Cognitive assessment; NMSS, Non-Motor Symptoms Scale; OFF, off-medication; ON, on-medication; PDQ-39,
39-item Parkinson’s Disease questionnaire; RDRS, Rush Dyskinesia Rating Scale; ROMP, Radboud Oral Motor Inventory for Parkinson’s
Disease; UPDRS, Unified Parkinson’s Disease Rating Scale. Significant values are shown in bold.
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The PD-HYP group had worse orofacial symptoms
and, specifically, higher difficulty with speech and
drooling of saliva scores (ROMP total score:
P < 0.0001; ROMP speech subscore: P < 0.0001;
ROMP saliva subscore: P = 0.001). There was only a
trend for difficulty in swallowing [ROMP swallowing
subscore, P = 0.06 (Fig. 1a)].
Finally, the PD-HYP group reported worse quality
of life, as measured by the PDQ-39 total score
(P = 0.03) and, more specifically, the subscores for
activities of daily living, social support and communi-
cation [P = 0.001, P = 0.01 and P <0.0001, respec-
tively (Fig. 1b)].
To evaluate possible differences in neuropsychological
profile and in frequency of MCI in the PD-HYP and
PD-no-HYP groups, we classified all patients as cogni-
tively intact, i.e. normal cognition (PD-NC) or MCI
(PD-MCI) [19]. Of the 89 PD patients recruited, 51 had
PD-NC and 38 had PD-MCI. The distribution of PD-
NC and PD-MCI in the two groups of patients with and
without hypomimia was similar (P = 0.5, chi-squared
test). After adjustment for multiple comparisons, perfor-
mance on all neuropsychological tests was similar in the
PD-HYP and PD-no-HYP groups (Table S3).
Multivariable regression analysis showed that the
degree of reduced facial expression (UPDRS-III item
19) was associated with age, severity of axial and
appendicular signs after correcting for disease dura-
tion, gender and dopaminergic therapy (Table 2).
Effect of levodopa on hypomimia
Figure 2 shows the effects of levodopa administration
in patients with and without hypomimia for UPDRS-
III total, appendicular, axial and facial expression-
scores. For UPDRS-III total score, there was a
main effect of the factor ‘group’ [F(1,87) = 23.1,
P < 0.0001], with the PD-HYP group having a signifi-
cantly higher score than the PD-no-HYP group. In
the presence of a ‘medication’ effect [F(1,87) = 332.1,
P < 0.0001], the two groups differed by magnitude of
response to levodopa (‘group’ by ‘medication’ interac-
tion: F(1,87) = 11.8; P = 0.0009). We found a similar
Figure 1 Differences between Parkinson’s disease (PD) with hypo-
mimia and PDwithout hypomimia in orofacial symptoms and
quality of life. PD patients with hypomimia had higher Radboud
OralMotor Inventory for Parkinson’s Disease (ROMP) total
score, and higher ROMP speech andROMP saliva subscores (a)
and reported worse quality of life according to 39-item Parkinson’s
Disease Questionnaire (PDQ-39) total score and PDQ-39 activities
of daily living (ADL), social support and communication subscores
(b).
Table 2 Univariable and multivariable regression analysis with










Axial score OFF 0.509 0.067 0.142 <0.0001
Appendicular score OFF 0.517 0.026 0.054 <0.0001
Gender 0.107 0.196 0.599 0.317
Age (years) 0.205 0.001 0.058 0.059
Disease duration 0.169 0.011 0.078 0.141
LEDD 0.144 0 0.001 0.218
Multivariable analysis
Age (years) 0.214 0.005 0.055 0.02
Axial score OFF 0.256 0.004 0.101 0.033
Appendicular score OFF 0.366 0.01 0.047 0.003
CI, confidence interval; LEDD, levodopa equivalent daily dose;
OFF, off-medication; ON, on-medication. Significant values are
shown in bold.
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pattern for the appendicular score, with a main effect
of ‘medication’ [F(1,87) = 366.9, P <0.0001] and
‘group’ [F(1,87) = 24.1, P <0.0001] and a significant
medication by group interaction [F(1,87) = 9.2,
P = 0.03]. Similarly, levodopa managed to improve
the axial score in both groups, albeit to a different
extent [effect of group: F(1,87) = 17.8, P < 0.0001;
effect of medication: F(1,87) = 217.1, P < 0.0001;
group by medication interaction: F(1,87) = 6.02,
P = 0.02]. Finally, levodopa improved facial expres-
sionin both groups [effect of group: F(1,87) = 122.8,
P < 0.0001; effect of medication: F(1,87) = 156.7,
P < 0.0001; group by medication interaction: F(1,87) =
26.7, P < 0.0001].
We then analysed the response of hypomimia to a
levodopa challenge only in the PD-HYP group
(N = 51; Table S4). There was a mean improvement
of 60.4  30.4% in UPDRS-III item 19 (facial expres-
sion) after levodopa intake (P < 0.0001 at Wilcoxon
test) along with a significant improvement in UPDRS-
III total score and all UPDRS-III subscores (all
P < 0.0001). Regression analysis was performed to
test which variables were associated with the improve-
ment of facial expression by levodopa (Table 3). At
univariable level, there was a significant association
between the improvement in facial expression and the
improvement in total, appendicular and axial
UPDRS-III scores. In the multivariable regression
model, the improvement in facial expression was
associated with the improvement of the axial score
only [b = 0.6 95% confidence interval= 0.3–0.9);
Figure 2 Differences between Parkinson’s disease (PD) with hypomimia and PD without hypomimia in motor symptoms severity. PD
patients with hypomimia had a significant higher score at Unified Parkinson’s Disease Rating Scale part III (UPDRS-III) total score
(a), facial expression (b), appendicular (c) and axial sub-scores (d). OFF, off-medication; ON, on-medication.
Table 3 Univariable and multivariable regression analysis with delta
of UPDRS-III item 19 as dependent variable in the group of









Age (years) 0.5 1.9 0.8 0.4
Gender 16.6 34.6 1.3 0.06
Disease duration (years) 0.1 1.7 1.9 0.8
D Axial score UPDRS-III 0.6 0.3 0.9 <0.0001
D Appendicular score
UPDRS-III
0.4 0.0 0.8 0.04
Multivariable analysis
D Axial score UPDRS-III 0.6 0.3 0.9 <0.0001
D Appendicular score
UPDRS-III
0.09 0.3 0.5 0.6
UPDRS-III, Unified Parkinson’s Disease Rating Scale, part III; D =
delta (see methods for details). Significant values are shown in bold.
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P <0.0001]. We found no association between facial
expression improvement and age, gender and disease
duration.
Discussion
Hypomimia is a well-recognized feature of PD, but its
clinical correlates have not been fully explored. In the
present study, we identified that people with hypomi-
mia had a more severe burden of motor symptoms,
including orofacial symptoms. They also had worse
apathy, but did not differ in terms of depression, anxi-
ety and cognitive profile. Finally, we demonstrated
that hypomimia was levodopa-responsive and the
extent of its improvement with medication was mainly
associated with reduction of axial symptoms. This
association occurred independently of age, gender and
disease duration.
Our data confirm that hypomimia is a frequent sign
of PD [4], occurring in up to 70% of patients in our
sample. Indeed, it is an underestimated and neglected
sign, mainly due to a lack of clinical rating instru-
ments and kinematic and neurophysiological mea-
sures, which may rate the different aspects of PD-
related facial impairment, including emotional dys-
function [20,21].
The association between hypomimia and worse
severity of motor scores on the UPDRS has been pre-
viously reported [4], in line with previous clinical
observations of lower fluidity of movement, speed of
talking, blinking, gesturing and vocal expressivity in
PD with hypomimia [22]. At an experimental level,
kinematic measures of posed smiling and voluntary
grinning in PD have been correlated with severity of
global dysfunction [21] and severity of motor symp-
toms of one body side, correlated with reduction of
expressivity of emotions in the ipsilateral hemi-face in
PD patients [23]. Accordingly, a common pathophysi-
ological substrate for hypomimia and motor symp-
toms in PD has been hypothesized, in that hypomimia
in PD is likely to reflect the abnormal activation of
the primary motor and pre-motor frontal areas by
dysfunctional basal ganglia [1,24].
A novel finding of the present study was that PD
with hypomimia was associated with more severe
axial and orofacial symptoms (speech, swallowing
dysfunction, and sialorrhea). Indeed, drooling tested
with clinical [25] or instrumental measures [13] has
been previously correlated with hypomimia, support-
ing the view that sialorrhea in PD is mainly caused
by an impairment of orofacial and swallowing
muscles [26].
Impairment of facial expression was not related to
cognitive impairment in our cohort of patients, as
performance in several neuropsychological tests was
comparable between the two groups. This finding
implies that PD with reduced facial expression can
have normal cognition [27]. Also, we did not find a
higher burden of depression and anxiety in PD-HYP,
in line with several neuropsychological reports docu-
menting hypomimia in non-depressed PD patients
[27,28]. This finding might be surprising when consid-
ering the previously documented association between
depression and reduced facial expression of emotions
in psychiatric patients [29]. However, it highlights the
different pathophysiological basis of spontaneous
facial activity and facial expression of emotions. Nor-
mal or even better expression of facial emotions (espe-
cially negative emotions) has been shown in patients
with major depressive disorders [30].
When considering non-motor symptoms, PD with
hypomimia was associated with worse apathy, a sign
associated with reduced striatal dopamine transporter
levels, independent of motor disability and depression
in PD patients without cognitive abnormalities [31].
The relationship we found between hypomimia and
apathy in PD possibly suggests a common pathophys-
iological background for the two abnormalities, likely
attributable to altered interaction between the basal
ganglia, prefrontal cortex and limbic system. Hence,
our findings support the view of face as a body region
where mechanisms related to different motor beha-
viour converge. From a clinical standpoint it is well
known that apathy is a common abnormality in PD
and that can severely affect the quality of life of both
patients and caregivers. Insight into the relationship
between hypomimia and apathy in PD could possibly
be relevant in guiding a more individualized approach
to the treatment of these symptoms.
Another relevant finding of the present study is that
hypomimia is primarily related to low dopaminergic
activity and it is a levodopa-responsive symptom.
Indeed, facial expression improved significantly after
levodopa intake, paralleling the improvement in limb
and axial motor symptom severity. This supports the
hypothesis that reduced facial expression in PD
should be considered a levodopa-responsive symptom
similar to other motor symptoms [3,32,33].
Our data also highlight that a reduction in facial
expression is associated with worse quality of life,
especially with regard to communication and activities
of daily living. This relationship has not previously
been identified. With relevance to this finding, some
recent observations based on relatively small case
studies, indicate complex interrelationships between
hypomimia, depression and social and subjective well-
being, which certainly require further investigation
[5,6,34].
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We acknowledge some limitations of the present
study. First, there was no objective method by which
to quantify facial expression. Second, we evaluated
only one aspect of facial impairment in PD, and we
did not include measures of emotional facial expres-
sion. Third, all patients taking dopamine agonists
used prolonged-release formulations, which were last
taken the morning before the test. Therefore, we could
not rule out a complete wash-out from these medica-
tions.
In conclusion, in the present study, we provide
novel information on the clinical correlates of hypo-
mimia in PD as well as data on its responsiveness to
levodopa administration. Our results indicate that
hypomimia is a common clinical feature in PD that
deserves attention during clinical examination because
it can have a negative impact in terms of the quality
of life of patients. The results also have some impor-
tant pathophysiological implications in that they sup-
port the hypothesis that hypomimia is mainly
attributable to decreased central dopaminergic tone
and is mainly associated with motor symptoms and
apathy. Future studies are necessary to clarify to what
extent hypomimia could also serve as a useful predic-
tor of the clinical course of PD and to shed light on
the relationship between hypomimia and impaired
facial expression of emotions in PD.
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